Indeed, the combination of vemurafenib, irinotecan and panitumumab/cetuximab has now been included in the National Comprehensive Cancer Network (NCCN) guidelines for the second line therapy of BRAF mutant CRC patients [29, 30]. This evidence concerns the gene BRAF and colorectal carcinoma.